Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Maeurer

Showing results (1-10 of 206) with videos related to

Pageof 21
Sort By:
Expert Review of Clinical Immunology|September 11, 2010
Markus Maeurer on the LifeGene projectMarkus Maeurer
Clinical Reviews in Allergy & Immunology|April 12, 2007
High-content T-cell and B-cell analysisMarkus Maeurer
Frontiers in Immunology|November 29, 2023
Editorial: Emerging talents in cancer immunity and immunotherapy: 2022Markus Maeurer
The Journal of Infectious Diseases|March 27, 2012
Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designsAlimuddin Zumla, Markus Maeurer
International Journal of Mycobacteriology|January 4, 2017
Host-directed therapies for multidrug resistant tuberculosisAlimuddin Zumla, Markus Maeurer
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2015
Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp DebatesAlimuddin Zumla, Markus Maeurer,
Science Translational Medicine|November 21, 2014
The host battles drug-resistant tuberculosisMarkus Maeurer, Alimuddin Zumla
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 27, 2015
The history of tuberculosis management in SwedenHelen Wallstedt, Markus Maeurer
American Journal of Respiratory and Critical Care Medicine|May 16, 2015
IFN-γ Release Assays for Risk Assessment in Contacts of Patients with Tuberculosis in Low-Burden European CountriesAlimuddin Zumla, Markus Maeurer
The Lancet. Respiratory Medicine|April 11, 2014
Totally-drug-resistant tuberculosis: hype versus hopeMarkus Maeurer, Marco Schito, Alimuddin Zumla
Pageof 21

Showing results (1-10 of 206) with videos related to

Sort By:
Pageof 21
Expert Review of Clinical Immunology|September 11, 2010
Markus Maeurer on the LifeGene projectMarkus Maeurer
Clinical Reviews in Allergy & Immunology|April 12, 2007
High-content T-cell and B-cell analysisMarkus Maeurer
Frontiers in Immunology|November 29, 2023
Editorial: Emerging talents in cancer immunity and immunotherapy: 2022Markus Maeurer
The Journal of Infectious Diseases|March 27, 2012
Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designsAlimuddin Zumla, Markus Maeurer
International Journal of Mycobacteriology|January 4, 2017
Host-directed therapies for multidrug resistant tuberculosisAlimuddin Zumla, Markus Maeurer
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2015
Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp DebatesAlimuddin Zumla, Markus Maeurer,
Science Translational Medicine|November 21, 2014
The host battles drug-resistant tuberculosisMarkus Maeurer, Alimuddin Zumla
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 27, 2015
The history of tuberculosis management in SwedenHelen Wallstedt, Markus Maeurer
American Journal of Respiratory and Critical Care Medicine|May 16, 2015
IFN-γ Release Assays for Risk Assessment in Contacts of Patients with Tuberculosis in Low-Burden European CountriesAlimuddin Zumla, Markus Maeurer
The Lancet. Respiratory Medicine|April 11, 2014
Totally-drug-resistant tuberculosis: hype versus hopeMarkus Maeurer, Marco Schito, Alimuddin Zumla
Pageof 21